ROCKVILLE, Md.--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ: MITI) today outlined a clinical development plan intended to support U.S. registration of its lead product candidate blinatumomab in patients with B-precursor relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL). The plan incorporates advice received from the U.S. Food and Drug Administration (FDA) within the context of a Type C meeting.
